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ABSTRACT

Prescription drug use continues to increase across the United States. An important
part of these medications are selective serotonin reuptake inhibitors (SSRIs) that function
as anti-depressants, and include drugs as citalopram (Celexa) and sertraline (Zoloft).
SSRI’s main mode of action is the inhibition of the serotonin reuptake transporter,
causing a buildup of extracellular serotonin, one of the neurotransmitters in the central
and peripheral nervous system. SSRIs can be considered persistent pollutants due to their
continuous release from wastewater treatment effluent, drug manufacturing effluent, and
agricultural runoff. Aquatic organisms can become non-target organisms when subjected
to sub-lethal concentrations (low ppb to high ppm) of antidepressants. Behavioral tests
provide sensitive endpoints for determining whether aquatic organisms have been
subjected to antidepressants, causing changes in their ecological fitness. The goal of this
research was to determine whether SSRIs cause sublethal effects in fish populations
through a change in feeding behavior, supported by brain and plasma chemistry and
changes in serotonin-related gene expression in the intestine. We hypothesized a decrease
in feeding behavior, a decrease in serotonin levels, and a change in gene expression after
exposure to sertraline and citalopram. Hybrid striped bass (HSB) exposed to citalopram
(6 day exposure at 50-150 µg/l) and sertraline (4-100 µg/l, 6 days exposure, 6 days
recovery) were fed every three days to determine effects on behavior. Blood, brain, and
intestine samples collected from euthanized fish every three days were analyzed for
concentrations of citalopram, sertraline and serotonin. Both sertraline and citalopram
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caused a change in predatory behavior during exposure, with sertraline having a more
dramatic effect than citalopram. The sertraline recovery period showed that the bass were
able to rapidly return to normal feeding behavior, even while the antidepressant was still
located in the brain and plasma. Citalopram and sertraline were both detected in brain and
plasma samples, but in different levels during the exposure and recovery period.
Serotonin levels also differed between each SSRI treatment. Our results showed that
SSRIs may cause an upregulation of both the serotonin reuptake transporter and
cholecystokinin, a satiation signaling protein. From an ecological standpoint an increased
feeding time could make exposed bass populations less ecologically fit compared to other
populations that are not as affected by antidepressants.
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CHAPTER ONE
LITERATURE REVIEW

Pharmaceutical usage
As the benefits of old and new pharmaceuticals becomes realized, the number of
drug prescriptions written continues to grow at an increasing rate. From 1999-2000, 44%
of the population took one prescription drug. By 2008, this proportion increased to 48%
[1]. In 2006, six of the most dispensed pharmaceuticals included the antidepressants:
citalopram, sertraline, duloxetine, venlafaxine, paroxetine, and bupropion [2]. Spending
on prescription drugs increased to 250 billion dollars in 2009 and accounted for roughly
12% of total personal health care expenses [1]. The number of prescriptions increased
from 254 million in 2010 to 314 million in 2015 [3].
Antidepressants include several classes including selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs),
norepinephrine and dopamine reuptake inhibitors (NDRIs), monoamine oxidase
inhibitors (MAOIs), and tricyclic. SSRI sales started in the mid-1980s. SSRIs were
developed to increase extracellular serotonin, which would beneficially help patient’s
mood and behavior. SSRI are prescribed to treat clinical depression, attention deficit
disorder, panic disorder, and obsessive-compulsive disorder [2]. In 2005, a Denmark
study reported 5% of adults were prescribed an antidepressant with 57% taking
citalopram and 14% taking sertraline [4]. The world economic co-operation and
development department reported a 60% increase in antidepressant use from 2001-2011
[5]. Sertraline has seen a substantial increase in consumption from 2007-2013 becoming
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the 60th most widely prescribed pharmaceutical overall [6]. In 2013, sertraline became the
second most dispensed psychiatric drug [7].
Pharmaceuticals entering the environment
Pharmaceuticals enter the environment from wastewater treatment effluent
containing drugs from human excrement, unmetabolized drugs, or disposal of unused or
expired drugs in toilets [2, 8, 9]. Livestock can be administered pharmaceuticals which
end up in solid or liquid wastes that run off agricultural fields [10]. Finally,
pharmaceutical manufacturing plants could release compounds into the environment
through their contribution of contaminated waters entering sewage treatment plants [10,
11]. Concentrations of pharmaceuticals in surface waters can range from ng/L to µg/L
levels.
Wastewater treatment facilities have limited ability to remove pharmaceuticals
from sewage [12]. Different wastewater treatment processes end in varying removal
efficiencies resulting in a discharge into surrounding waters [13]. Citalopram has the
highest removal efficiently of the SSRIs at 98%, while sertraline has the lowest at 60%
[4]. Studies in several countries reported antidepressants in wastewaters (0.15-84,000
ng/L), surface/ground waters (0.5-8,000 ng/L), and drinking waters (0.5-1,400 ng/L) [5,
14]. Three different sewage treatment plants found citalopram in a range of
concentrations from 382 ng/L to 612 ng/L [15]. Many treatment plants use primary and
secondary removal systems such as activated sludge and biological degradation to clean
wastewaters [16]. Installation of advanced tertiary removal systems (nanofiltration,
reverse osmosis, UVC photolysis, ozonation) may result in increased removal efficiencies
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[13, 16, 17]. Doctors chronically administer drugs for the upkeep of therapeutic effect for
patients, resulting in frequent enough discharges to make pharmaceuticals persistent
pollutants leading to continuous exposure over an aquatic organism’s life cycle [15, 18,
19].
SSRIs occur in a variety of different environmental matrices making them
the most common detected human pharmaceuticals in aquatic habitats [5]. Sertraline has
been analyzed around the United States and showed an average wastewater concentration
range of 78-120 ng/L [20]. A small creek in Texas registered sertraline levels averaging
4.27 ng/L [21]. Downstream from a wastewater treatment plant in Iowa, researchers
detected ten different antidepressants in two streams including sertraline (0.7-37.5 ng/L)
and citalopram (4.58-205 ng/L) [9]. Antidepressants had high sorption coefficients
(reported as Koc values which are organic carbon normalized sorption coefficients) in
soils and sediments. Research reported the antidepressant fluoxetine has the lowest
sorption rate while citalopram had the highest [5]. Scientists observed high brain
antidepressant concentrations at wastewater treatment outflows, while concentrations
remained elevated in the brain further downstream from the effluent pipe [9]. SSRI
mixtures in natural environments showed combined concentrations up to 3,000 ng/L near
treatment plant outflows [3].
Most pharmaceuticals that enter the environment could potentially be persistent in
aquatic ecosystems. Persistence of such pollutants could pose life-cycle problems to the
aquatic biota [22]. Research shows lethal effects of antidepressant pharmaceuticals on
aquatic life occur at concentrations over 1 mg/L, far from environmental relevance [23].
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These compounds appear at low levels, so observation of chronic sublethal effects occur
more than acute effects [12, 15]. Sublethal effects from pharmaceutical exposure could
result in long-term changes from the individual to population level after several
generations of exposure [11, 15].
Pharmaceutical partitioning
When looking at several pharmaceutical compounds, log Kow accounted for less
than 50% of the variation suggesting more than the Kow is needed to understand
environments favorable for some compounds [13]. Different properties of a drug dictated
partitioning behavior such as dissociation constant, molecular weight, lipophilicity, and
pH of adsorption site [24]. Kow cannot be solely relied on for understanding partitioning
of antidepressants due to the ionizable drug characteristics. Compounds that showed
ionizable functional groups tended to move away from lipid environments whereas nonionizable compounds tended to move towards lipid environments. Relying on just Kow
values could lead to inaccurate fish tissue partitioning estimates for antidepressants [13].
Researchers investigated toxicity and bioaccumulation of ionizable drugs took
into account pH to increase the success of ecological risk assessments [24]. The
bioavailability of ionizable xenobiotics’, including pharmaceuticals, changes depending
on the compound’s ionization state. Neutral compounds can cross cellular membranes
with ease compared to their ionized counterparts, making the neutral compounds more
bioavailable [25]. Pharmaceuticals distributed throughout the body depend on the
ionization state created by the pH ranges found in the body [24]. Ionization state alone
cannot explain pharmaceutical toxicity. Fish models investigated the problem by

4

measuring how excretory products changed pH in the fish’s immediate environment. The
pH change could ionize compounds making them more likely to be absorbed or prevent
compounds from crossing cellular membranes [25]. SSRIs are weak base
pharmaceuticals with pKa values ranging from 9.05-10.5 [5]. SSRIs in neutral pH
aqueous solutions will be found in their ionic form more than their un-ionic form.
Sertraline (a SSRI) showed increased toxicity to fathead minnows as the percentage of
un-ionized drug increased [25].
Antidepressants concentrate in different tissues within fish. Lipophilic xenobiotics
including SSRIs primarily enter fish through the gills while exposure through feeding and
water intake is less significant [15]. Low water temperatures decreased ventilation rate
and metabolism causing decreased water and pharmaceutical intake [26].
Pharmaceuticals that entered the fish via the gills bypassed first pass metabolism in the
liver before systemic distribution. Antidepressants and their metabolites may distribute to
the liver, brain, plasma, and muscle of fish, but more research is needed to determine the
relative levels getting into these target tissues [27].
European agencies outlined a process to determine the environmental risk of
human pharmaceuticals. The first phase predicted environmental concentrations using the
market percentage, max daily dose, wastewater per inhabitant per day, and dilution
factors [28]. Some examples of human daily doses for SSRIs are 0.01, 0.01, 0.02 and
0.02g for escitalopram, citalopram, fluoxetine, and paroxetine respectively. Sertraline and
fluvoxamine have higher daily doses of 0.05 and 0.1g, respectively [5]. A predicted
environmental concentrations below 0.01 µg/L resulted in no further tests due to the low
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environmental threat of that compound. A predicted environmental concentration higher
than 0.01 µg/L led to more tests (second phase) due to a potential environmental threat.
The second phase used biodegradability tests to investigate wastewater treatment
facilities and the environment. These tests investigated sorption behavior of the drug to
sewage sludge, soil, water, and octanol [28].
Microcosms provided an excellent tool for analyzing the environmental risk of
pharmaceuticals over several trophic levels that could not be completed with singlespecies tests [29]. Results from microcosm experiments suggested antidepressants could
potentially bioaccumulate in aquatic species at distances up to 1 km from effluent
discharge in the St. Lawrence River; showing antidepressants can be transported great
distances in surface waters [9, 12]. Difficulties can arise when trying to make
comparisons between multiple studies since the medium of exposure (microcosms, lakes,
and rivers), ambient concentrations of antidepressants, exposure time, and fish species
were different [12].
Serotonin and the serotonin reuptake transporter
Serotonin, a common neurotransmitter, was found in several species of
fish, and serotonin synthesis and function shows high conservation between invertebrates
and vertebrates [5, 8, 15]. Tryptophan hydroxylase synthesizes serotonin from tryptophan
in the central nervous system and gastrointestinal tract [4, 15]. Tryptophan concentration
limits the rate of serotonin synthesis in the fish brain [30]. Invertebrate research
hypothesizes serotonin controls gonadal maturation and induction of spawning and
metamorphosis along with metabolism and behavior [5, 29]. Developmental biology
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confirmed serotonin appeared first during brain development and helped in the regulation
of cell proliferation, differentiation, and apoptosis [31].
Both mammals and teleost fish exhibit homologies in the hypothalamic-pituitaryadrenal axis, resulting in the use of neurotransmitters to maintain autonomic, behavioral,
and stress responses [32]. Serotonin can both, directly and indirectly, stimulate the
release of gonadotropin releasing hormone and gonadotropin luteinizing hormone from
the hypothalamus and pituitary gland [19]. Research hypothesizes stimulation of the
hypothalamus-pituitary axis by serotonin controls the release of corticotrophin releasing
hormone during non-stressful conditions and adrenocortical releasing hormone during
stressful conditions [30]. Delayed elevation of serotonin in some brain areas could cause
changes in behavior, endocrine, and reproductive systems [8, 30]. Research suggests
serotonin influences behavioral changes in feeding, appetite, and locomotion [11, 32].
Compounds in addition to serotonin might explain behavioral changes seen in the
literature. A study by Conners et al. (2009) demonstrated decreased foraging behavior in
tadpoles after serotonin controlled brain activity which regulated corticotrophin-releasing
factor (CRF) changed behaviors in the hypothalamus [33].
The serotonin reuptake transporter (SERT) is an enzyme responsible for
controlling intra and extracellular serotonin concentrations. SERT is the main target for
selective serotonin reuptake inhibitors (SSRIs) which have structural differences but
work by the same mode of action [18]. SSRIs therapeutic effect increases serotonin in the
synapse by blocking SERT ATPase activity [12, 34].
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Available information on mammalian pharmacology may be helpful for
predicting fish responses if the species have similar target receptors to previously studied
pharmaceuticals [21]. Research has shown similarities exist between enzymes and
receptors in aquatic species and humans, suggesting pharmaceuticals have the ability to
affect aquatic non-target organisms [35, 36]. Danio rerio, Daphnia pulex, and
Chamydomonas reinhardtii (green algae) showed 86%, 61%, and 35% similarities,
respectively when compared to 1,318 human drug targets. The study showed lower
invertebrates and plant species have the potential to respond to pharmaceuticals in the
environment due to conserved drug target receptors [37]. Serotonin receptors have been
detected in several fish species including Japanese medaka (Oryzias latipes), three-spined
stickleback (Gasterosteus aculeatus), goldfish (Carassius auratus), hybrid striped bass
(Morone chrysops x Morone saxatilis), and zebrafish (Danio rerio) [8, 21, 38]. Studies
that compared SSRI receptors in different species, at the amino acid level, determined
fish, on average, have more highly conserved receptors for SSRIs than other species more
closely related to humans [38]. Zebrafish (Danio rerio) have two genes which code for
SERT with 66-69% and 75% conserved compared to human SERT [34]. SERT sequence
conservation jumped to 93% when amino acid residues were compared [3]. SERT
binding affinity showed similarities between model organisms such as fathead minnows,
zebrafish, and laboratory rats [34]. The hybrid striped bass SERT showed 72% homology
with human SERT [38]. Sweet (2015) determined the conservation of the functional
domain for SERT was similar between the hybrid striped bass and mammals. Different
SSRIs were tested to determine which had the highest binding affinity for the hybrid
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striped bass SERT. The antidepressants rank similarly from highest to lowest binding
affinity in fish and humans: sertraline > fluoxetine > citalopram > venlafaxine [38, 39].
Ecotoxicology of pharmaceuticals
Non-target organisms with similar drug receptors may be at heightened risk for
exposure to pharmaceuticals even at low concentrations [25]. Pharmaceutical companies
performed numerous tests to develop nonclinical safety profiles for their drugs. The
amount of mammalian data is extensive but only a few proposed models investigated
ecotoxicological effects using mammalian data to prioritize pharmaceuticals [38].
Researching different behavioral endpoints for toxicity could improve our understanding
of pharmaceuticals on fish populations [40]. Behavior correlates with ecological fitness at
individual and population levels. A change in behavior can result in tradeoffs that cause
changes in individual fitness or population increase/decrease/local extinctions [8, 11, 41].
Population-level changes depend on the trophic level first affected leading to potential
negative consequences in other trophic levels [11].
When a drug’s chemical half-life exceeds effluent release rate, characterization of
chronic and sublethal effects on aquatic organisms should be examined [23]. Sublethal
effects include changes in behavior. A behavior describes a sublethal response of an
organism to biotic and abiotic stimuli [34]. The responses can vary in type, intensity, and
time of occurrence depending on physiological signals and environmental or social
tolerance ranges [22, 34]. Behaviors describe necessary mechanisms organisms use to
react and adapt to changes in the environment, such as exposure to pharmaceuticals [22].
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Behavioral endpoints provide the most sensitive ecotoxicological approach to
studying pharmaceuticals in the environment [22, 25]. Past research reported behavioral
responses could be 10 to 100 times more sensitive than standard endpoints such as
survivorship [22, 25]. Out of several different endpoints used in determining ecological
risk assessment, feeding rate showed more sensitivity as a toxicological response than
standardized endpoints such as growth or survivorship [25, 34]. When exposed to a
toxicant organisms try and reverse their effects, and changes in behavior can be the first
to show [22]. Studies have linked other biomarkers, including neurotransmitters, plasma
enzymes, oxidase activity, hormones, and energy metabolism, to behavior [5, 22].
Many antidepressants work by effecting neurotransmitters in the brain to cause
their therapeutic effects. The dose of antidepressants and the time exposed can have
profound effects on physiological endpoints [11]. Research showed neurotransmitters
such as serotonin, dopamine, and norepinephrine influenced locomotion, aggression, and
feeding behaviors in fish [22]. Effects included delays in reproductive and physiological
development, decreased aggressiveness, and inhibition of feeding responses [5].
Sensitivity in behavioral endpoints could be ranked with locomotor behavior and early
life stage behavior as most sensitive followed by reproductive behavioral changes [11].
Feeding changes may not be apparent from growth data depending on food availability
[25]. Fluoxetine and venlafaxine research demonstrated changed water column
positioning, decreased the ability to capture prey, and delayed escape response at
concentrations of 23.2-100.9 µg/L [23, 38]. Another study discovered reduced territorial
aggression in coral reef fish along with decreased locomotion and aggression in Siamese
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fighting fish [11]. Drummond and Russom (1990) exposed fathead minnows to 300
organic chemicals to determine how to categorize changes in behavior [42]. They
determined three acute behavioral toxicity syndromes occured: hypoactivity,
hyperactivity, and physical abnormality. Hypoactivity resulted in decreased motion
linked to narcotic activity [22]. Hyperactivity described accelerated motion, increased
ventilation and changed metabolism. Physical abnormality categorized convulsions and
bone deformations happening from damage to the nervous system [22].
Behavioral changes could cause ecological consequences including deviations in
predator-prey interactions [22]. Evidence suggests long-term exposures to SSRIs changed
hierarchies in fish populations during sensitive times in the reproductive cycle. The
ecological health of a population could shift to fish who were originally subordinate
compared to the previously dominate fish [15]. The first indication of behavioral changes
become apparent between 50-70 minutes to a few days after the start of exposure to
antidepressants or tryptophan [43]. Variations in feeding behavior could decrease the
nutritional status of the organism affecting their ecological fitness [3]. Deviations in
neuromuscular behavior may impair food search and reproductive behavior which
increases the risk of predation [44]. Larval fathead minnows showed reduced predator
avoidance when in an environment with fluoxetine and venlafaxine at concentrations of
25-250 and 500-5000 ng/L, respectively [9]. Pharmaceuticals may, therefore, cause
behavioral changes in the biochemical, individual, and population levels of aquatic
ecosystems [34].
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Experiments completed with a complex mixture of SSRIs resulted in whole brain
serotonin levels decreased by 44% ± 11% by the third day of exposure. By the 9th day of
exposure whole brain serotonin levels decreased by 83% ± 7% compared to controls. At
day 12, all treatments showed a decrease in whole brain serotonin between 40% - 80% ±
4%. Days 9-12 were a recovery period, but whole brain serotonin levels remained
significantly lower than controls [38]. Knowing the plasma concentrations of SSRIs in
fish could help predict toxic effects [27]. SSRI levels in fish plasma did not change
between 48 and 72 hours after exposure, suggesting concentrations reach their maximum
in fish at 48 hours [38]. One study reported pharmaceutical uptake, including
antidepressants, in bull sharks (Carcharhinus leucas) in river systems. Citalopram was
one antidepressant found in the plasma at concentrations of 0.4 ng/mL [45].
The brain is the first organ of interest many times in antidepressant research.
Other organs have the potential to be mechanistic sites for SSRIs such as the intestine
[46]. Serotonin stimulates and inhibits gut motility depending on the section of the gut
[47]. Researched showed higher serotonin concentrations in the whole anterior intestine
with lower concentrations in the entire posterior intestine of rainbow trout [46].
Serotonergic neurons in teleost fish can develop into different morphologies and densities
with the two most abundant forms being enterochromaffin (EC) cells or enteric neurons
[47]. Enteric neurons make up a chain of serotonergic neurons that go up and down the
intestine walls [48]. EC cells dominate production of serotonin in the gut. The release of
serotonin from EC cells regulates peristalsis, secretion, vasodilation, and perception of
pain/nausea [48]. While mammalian intestines contain a large amount of EC cells, some
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teleost species have a low number of EC cells or none at all, meaning enteric neurons
could be larger producers of serotonin in the fish gut [46]. The serotonin-selective
reuptake transporter (SERT) is expressed in the intestinal mucosa serving as a critical
molecule for removing serotonin from the intestine space after release from EC cells or
enteric neurons [48].
Changes in behavior linked to SSRI exposure may be affecting gene expression
within the intestine walls. One hypothesis states changes in feeding behaviors could be a
result of up or down regulation of hunger signals from within the gut [49]. Production of
cholecystokinin (CCK) takes place in both the brain (CCK-8) and the gut (CCK-A) [50].
CCK has been isolated from the gut of several fish species including trout and cod [49].
CCK appetite control was demonstrated in studies with goldfish and trout [49]. CCK will
only be released in the gut in the presence of food and may mediate another protein
(leptin) effect on food intake [50]. SSRI exposure could cause a down-regulation in
SERT [25]. A pharmacological blockage of SERT could lead to an increase in serotonin
in the intestine, where serotonin would move to the blood stream and be removed by
platelets expressing SERT [48]. The gene for intestine SERT is expressed downstream
from SERT found in brain neurons, making the two serotonin transporters similar [48].
Current citalopram research
Citalopram has two forms; the S (+) enantiomer (escitalopram) represents the
more active form [5, 14]. Research showed the S (-) enantiomer (citalopram) could
disrupt the effects of escitalopram interacting with the SERT receptor [31]. Citalopram
half-life is roughly 36 hours [4]. Excretion of the active drug and its main metabolite
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(desmethyl citalopram) contribute to 26% and 19% of the human daily dose (40 mg/day),
respectively [15, 27]. The ecotoxicological risk of citalopram to aquatic organisms with
nervous systems containing serotonin, such as fish, has not been well studied [4].
Previous research hypothesized citalopram has the lowest toxicity of the SSRI
compounds with LC50 of 3.9 mg/L and NOEC of 0.8 mg/L [4, 5].
Previous research on citalopram investigated the effect of exposure through
dietary routes. Holmberg et al. (2011) studied citalopram exposure through feeding
juvenile rainbow trout citalopram soaked food at environmentally relevant
concentrations. The researchers determined whether citalopram caused behavioral
changes in aggression or reproduction. No significant changes were found in aggressive
behavior or swimming activity between exposure groups [43]. A similar experiment
exposed trout to 100 µg/kg of citalopram in pellet food for one week [30]. After seven
days of exposure, previously dominant fish became less aggressive and showed decreased
cortisol levels compared to controls, but no difference was seen when compared to a
tryptophan-supplemented diet [30].
Behavioral experiments exposed aquatic organisms to citalopram via a solely
aqueous exposure route. Endler guppy behaviors measured after a chronic exposure for
21 days to 2.3 µg/L or 15 µg/L citalopram saw decreased feeding time and decreased the
freezing frequency at 15 µg/L. All the behaviors studied directly correlated with anxiety
[19]. A decrease in anxiety can have detrimental effects on the survival of organisms,
leaving them more vulnerable to predation and resulting in decreased feeding success [5].
Olsen et al. (2013) hypothesized that SSRI exposure disrupts the hypothalamic-pituitary-
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interrenal axis (HPI-axis) causing changes in freezing, exploratory, and feeding behaviors
[19]. Feeding behavior of three-spined stickleback exposed to 0.15 or 1.5 µg/L
citalopram was investigated for 21 days [14]. The number of attacks on prey
(bloodworms) was observed during a 10-minute span, weekly. Fish decreased their
number of attacks on prey (by 37.5%) after the first week. This behavior persisted
throughout the experiment, and both exposure concentrations showed significant
differences from controls, but no differences from each other. The researcher used three
fish per tank providing a more realistic experiment since three-spine stickleback are not
solitary fish [14].
Current sertraline research
The chemical properties confirmed for sertraline include a pKa of 9.47, a half-life
of 37 hours, photodegradation period of 4-11 days, and average therapeutic dose of 50
mg/day with an internal human therapeutic value of 0.19 µg/ml [4, 15, 25, 53]. Sertraline
breaks down in the body to desmethylsertraline [21]. In Canada, sertraline detected in
incoming wastewaters reported values as high as 47 kg total, annually [27]. Researchers
hypothesize sertraline inhibits Na/K ATPase activity in the brain [12]. Research
hypothesized sertraline may affect oxidative stress and acetylcholinesterase activity [25].
A decrease in acetylcholinesterase activity suggests dysfunction of ventilator and
locomotion as well as inhibition of anti-oxidant enzymes [5]. Some of the antioxidant
enzymes (which protect organisms from reactive oxygen species) affected by sertraline
include superoxide dismutase, catalase, glutathione peroxidase, and glutathione Stransferase [25].
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Sertraline has been documented as the most toxic of the SSRI class. One
hypothesis examined the higher log D (used in pharmacology research and quantifies the
distribution of a drug at different pH values) value compared to the other SSRIs, resulting
in higher bioaccumulation numbers [6, 38]. Sertraline exposure resulted in higher brain
concentrations than would be suggested by surrounding water concentrations [23].
Several studies reported sertraline in fish fillet and liver tissues at up to 19 and 545 ng/g,
respectively [13]. Subtle changes in the chemical structure of SERT receptors could
result in the slight differences in serotonin concentrations seen in the literature [23]. The
pH should also be considered with sertraline because aqueous exposure can result in fish
plasma levels much higher than human therapeutic doses [51]. Ionization of sertraline
relied on the pH of the external and internal environment. Research hypothesizes the unionized form of sertraline moves to target sites at a more rapid pace than the ionized form
[25].
Studies completed with sertraline documented changes in behavior. Fathead
minnows exposed to sertraline showed an anxiolytic effect with fish spending 18-42%
less time under shelter compared to controls, leaving fish more vulnerable to predation
[34]. Crucian carp exposed to 80 and 300 ng/L sertraline reported increased excessive
swimming, decreased feeding rate, decreased food consumption, and decreased shelter
seeking. Sertraline was detected in the highest concentrations in the carp liver and brain
[40]. Perch feeding was reduced by as much as 60% when exposed to 89 and 300 µg/L
sertraline over 7 days [54]. A decrease in feeding could change the balance of
predator/prey relations and community structure [5]. Tadpoles exposed to
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environmentally relevant concentrations of sertraline and fluoxetine (0.1, 1, and 10 µg/L)
showed developmental effects over a 70-day exposure. Sertraline concentrations in
tadpoles at day 44 were 6x higher compared to fluoxetine. Growth decreased by 35%,
and tadpoles completed tail resorption 10 days earlier than control tadpoles at the 0.1 and
1 µg/L concentrations [33]. Crab populations off Portugal exposed to sertraline reported
significant decreases in AChE activity, increased GST biotransformation, and increased
oxidative damage [44]. Sertraline exposure to zebrafish embryos resulted in increased
abnormalities for tail, yolk-sac, and head at 100 µg/L at 32 hours post fertilization [7].
Sertraline (424 ng/L) exposed crayfish were more aggressive than control crayfish [53].
Few studies involving behavioral endpoints correlate their research to
biochemical endpoints, the brain and plasma have been the focus of biochemical research
involving sertraline. Sweet (2015) documented a decrease in whole brain serotonin levels
for a SSRI mixture involving sertraline. This result is hypothesized to be a result of the
SERT receptors not becoming desensitized within the short exposure time. Sertraline
exposure may have caused a decrease in the total density of SERT receptors in the tissue
suggesting a down-regulation of SERT with long-term exposure [38]. The greatest
sertraline concentrations were observed in bull shark livers, mainly thought to be a result
of the liver being the place for xenobiotic metabolism [5].
Thesis Goals
Our lab has worked on antidepressant exposures to hybrid striped bass in the past.
Sweet (2015) exposed hybrid striped bass to a SSRI mixture including fluoxetine,
sertraline, and citalopram, and showed an increase in time to capture prey, with assumed
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additivity between compounds [38]. A fluoxetine only exposure was already completed
before, leaving a gap with no data on citalopram or sertraline only exposures. All studies
used a similar experimental setup consisting of six days of exposure followed by six days
of recovery. Bass were fed every three days to gather predatory behavior data. Analytical
data collected varied between studies, with whole brain serotonin being the common
parameter of interest. Completely understanding mixture data is difficult without having
information on the effects of the individual compounds. The main goal of my thesis was
to gather data on how sertraline and citalopram, individually, affected feeding behavior
and brain chemistry in hybrid striped bass. In addition to brain chemistry analysis, we
also investigated gut tissue to see if changes in serotonin transporters and CCK levels in
this part of the body can help further explain the changes in predatory behavior. The
following objectives helped us meet this goal.
1. Determine if exposure of hybrid striped bass to sertraline causes changes in
predatory behavior, brain chemistry, and intestinal gene expression.
2. Determine if exposure of hybrid striped bass to citalopram causes changes in
predatory behavior and brain chemistry.
3. Determine how patterns from the previous SSRI mixture exposures compare to
the individual SSRI exposures.
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CHAPTER TWO
EFFECTS OF SERTRALINE ON HYBRID STRIPED BASS PREDATORY
BEHAVIOR, BRAIN CHEMISTRY, AND GUT GENE EXPRESSION

Introduction
Due to the growing knowledge on the benefits of pharmaceuticals, their use
increased in the United States to 314 million prescriptions in 2015 [1]. As a result of this
increased use, more pharmaceuticals are finding their way into our wastewater.
Unfortunately, wastewater treatment plants do not completely remove pharmaceuticals
during treatment and as a result these chemicals can enter the environment [2-5].
Selective serotonin reuptake inhibitor (SSRI) antidepressants are among the most
commonly detected compounds and have been detected in the environment at
concentrations ranging from low ng/L to µg/L concentrations [4, 6-10]. One of the most
commonly prescribed antidepressants, sertraline has a removal efficiency of 60% by
wastewater treatment plants [11]. The release of SSRIs in wastewater effluent is frequent
enough to consider these drugs pseudo-persistent pollutants [12-14]. Non-target
organisms with conserved or similar drug receptors could be affected by exposure to
SSRIs into the environment [15, 16].
Sertraline became the second most dispensed psychiatric drug in 2013, and is
used to treat many depressive disorders [5, 17]. The mechanism of sertraline, as with all
SSRI class drugs, involves blocking the serotonin reuptake transporter (SERT). SSRIs
block the reuptake of serotonin back into the pre-synaptic neuron causing a buildup of
extracellular serotonin [5, 18]. Research has demonstrated low serotonin causes
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behavioral changes in feeding, appetite, and locomotion [19, 20]. Serotonin and SERT
are highly conserved between species [3, 21, 22]. SERT has been positively identified in
fish species including Japanese medaka (Oryzias latipes), three-spined stickleback
(Gasterosteus aculeatus), goldfish (Carassius auratus), hybrid striped bass (Morone
chrysops x Morone saxatilis), and zebrafish (Danio rerio) [18, 21]. In hybrid striped bass,
the SERT receptor shows 72% homology with human SERT [21].
Research suggests sertraline as the most toxic of the SSRIs due to its high log D
(used in pharmacology research and quantifies the distribution of a drug at different pH
values) value resulting in higher bioaccumulation [23]. Sertraline has been reported to
have tissue levels as high as 545 ng/g tissue after fish were sampled from five effluent
dominate rivers across the United States [10]. Fathead minnows exposed to sertraline
demonstrated 18-42% less time seeking shelter compared to controls [8]. Perch exposed
to 89, and 300 µg/l sertraline saw feeding decrease by up to 60% after a 7-day exposure
[24]. Crayfish showed more aggression towards intruders than controls when exposed to
an environmentally relevant concentration of 424 ng/L sertraline [25].
Little research has been done looking at other modes of action for sertraline
outside of the brain. Serotonergic neurons are found in high levels in fish intestines [26].
The release of serotonin in the gut may be responsible for regulating peristalsis, secretion,
vasodilation, and perception of pain/nausea [27]. Research has hypothesized that SSRIs
may be able to regulate the gene expression of SERT [21, 28]. Cholecystokinin (CCK) is
a peptide responsible for the hunger signals within the gut and has demonstrated the
ability to control appetite in gold fish and trout [29].
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Previous research by Sweet (2015) showed decreased serotonin levels in the brain
of hybrid striped bass correlated with an increase in time to capture prey using an
environmentally relevant SSRI mixture that included sertraline [21]. The goals and
hypotheses of this study were to (1) determine the effects of only sertraline on the ability
of hybrid striped bass to capture pre; where sertraline was expected to increase bass time
to capture prey, (2) quantify the amount of antidepressant reaching the brain and how it
affects serotonin levels; where sertraline would be detected in the brain and cause a
decrease in serotonin, (3) determine fish plasma antidepressant levels; where sertraline
would be detected in the plasma, and (4) investigate whether sertraline causes and up or
down regulation of CCK or SERT in the hybrid striped bass intestines; where exposure to
sertraline would cause and up regulation in the genes. Few studies using sertraline as a
toxicant correlated serotonin levels in the brain with behavioral endpoints. From our
knowledge, this study is one of the first to investigate the effects that SSRIs could play in
the fish intestine.
Material and Methods
Test chemicals
Sertraline hydrochloride was purchased from TCI chemicals. Acetone, HPLC
grade methanol, HPLC grade acetonitrile, glacial acetic acid, trace metals grade HCl,
triethylamine, Optima® LC-MS methanol, Optima® LC-MS formic acid, molecular grade
ethanol, molecular grade chloroform, molecular grade isopropanol, glycoblue, DEPC
water, RNase away, ultrapure water, and RNAsecure (Ambion) were purchased from
Fisher Scientific. STAT-60 was purchased from Tel-Test Inc. (Friendswood, TX, USA).

28

Internal Standard fluoxetine-D5 hydrochloride was purchased from CDN Isotopes
(Quebec, Canada). MS-222 was purchased from Pentair aquatic habitats (Apopka, FL,
USA). Serotonin creatine sulfate complex and Fluka LC-MS Chromasolv® water were
purchased from Sigma Aldrich (St. Louis, USA). Water used for analytical procedures,
excluding LC-MS/MS, was ultra-purified using a Milli-Q Super-Q filtration system
(Millipore) with a measured resistivity of 18 MΩ x cm.
Fish
All experiments were conducted under the supervision of Clemson University
Animal Care and Use Committee using approved animal use protocols (AUP 2015-077,
AUP 2014-015). Hybrid striped bass (Morone saxatilis x Morone chrysops) were
purchased from Keo Fish Farms (Keo, AR, USA) as fingerlings. Bass were kept in 300450L holding troughs at the Cherry Farm aquatic research lab maintained by Clemson
University (Clemson, SC, USA). Troughs were constantly supplied with fresh water (pH
6.45 ± 0.17, hardness 24 mg/L as CaCO3, alkalinity 10 mg/L as CaCO3) as flow through
from Lake Hartwell (Clemson, SC, USA). Water coming into Cherry Farm was first
filtered through a gravel bed and sterilized with UV radiation. Water temp was
maintained between 19 and 24 °C using heated or chilled water depending on incoming
water temperature. Air stones and agitators (Boatcycle Inc., Henderson TX, USA) were
used to maintain oxygen levels in tanks and troughs. Zeigler Bros, Inc. (Gardners, PA,
USA) commercial diet (Finfish Gold crumble, 1.0 mm, 2.0 mm, and 5.0 mm slow sink)
was used to feed bass until they reached appropriate size (23 ± 1.81 cm; 131.6 ± 24.8 g).
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Fathead minnows (3-4 cm) were purchased from Anderson Minnow Farm
(Lonoke, AR, USA). Minnows were kept in 100L troughs with flow through system
bringing in the same water as above. Until use, minnows were fed a commercial diet
(Tetramin® Tropical Flakes) purchased from Dr’s Foster and Smith Inc. (Rhinelander WI,
USA).
Bass training
Once bass were of the appropriate size (approximately 6 months to 10 months
old), they were trained to capture live prey. Bass were randomly chosen (30-35 bass) and
moved to a separate 300L trough for group training. During group training, 5 minnows
per bass were dropped into the trough every 3 days over a 6-day period. On the 6th day of
group training, bass were moved to individual experimental tanks (1 bass per tank).
Bubble aerators were placed in each tank and two grates on top to prevent the bass from
jumping out. During individual training, the aerator was removed from the tank and bass
were given a few minutes to acclimate. Each bass was fed 4 fat-head minnows, dropped
into the tank at the same time, every 3 days over a 6 day span. The time to capture each
prey was recorded and used to determine which fish were appropriate to use in the
exposures. Bass who ate at least 3 minnows (with comparable feedings on the previous
training days) were used in the exposure.
Experimental design
Hybrid striped bass were exposed to sertraline in a static system for 6 days
followed by 6 days of recovery time. Exposure tanks purchased from Deep Sea Aquatics
were 119L and measured 92.1 cm x 32.4 cm x 40 cm. Each tank had a 1.9 cm PVC
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vertical standpipe drilled into the front glass for maintaining water volume when used as
a flow through system. Water for the experiments was also taken from Lake Hartwell
similar to the holding troughs. Additional filtration through a multi-resin filtration system
(Water and Power Technologies, Columbia, SC, USA) was used for additional cleanup
before sending water to the tanks. Water quality parameters (pH, DO, and temperature)
were measured during the feeding events using a YSI 556 multi-parameter instrument
(Yellow Springs Instruments). Work previously completed in this lab demonstrated that a
6 day static exposure did not result in levels of total ammonia nitrogen or free ammonia
that was acutely toxic to the fish, thus affecting the behavioral endpoints.
Behavioral tests followed procedures previously done in our laboratory [21, 30,
31]. On the last individual training day (exposure day 0), 4 minnows were dropped into
the tank and bass were given 25 minutes to consume all prey. The time each bass took to
consume each prey was recorded and then 1500 seconds (25 minutes) was recorded if any
minnows were failed to be consumed. The tanks were filled to 80L and marked before
turning the water off and spiking the tanks. Each bass was randomly assigned to a
treatment (5 bass/treatment/time point) and spiked with the appropriate volume of
sertraline to reach nominal concentrations. Feeding days took place on days 3, 6, 9, and
12. After feeding on day 6, the water flow was returned to each tank to start the recovery
period of the experiment. After each feeding, 5 bass per treatment were euthanized for
brain, plasma, and intestine analysis.
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Sertraline exposure
Stock solutions (prepared fresh daily) of sertraline were prepared by dissolving
sertraline HCl in methanol and then added to tanks to reach their nominal concentrations
(4, 40, and 100 µg/l). Low, medium, and high exposures were performed in addition to a
control. The highest concentration equivalent of methanol was added to each control tank
to ensure no toxicity form the carrier solvent. Methanol was at a concentration less than
0.1 mg/L; compliant with ASTM international recommendation for experiments
involving fish (ASTM1241-05). Two hours after tanks were spiked, appropriate aliquots
from each tank were taken to measure sertraline concentrations.
Sertraline analysis
Sertraline concentrations were analyzed on day 0, 2 hours after spiking the tanks.
Water samples were acidified with 2-3 drops 2N HCl (pH of 3.0) and extracted using C18 solid phase extraction cartridges. Cartridges were conditioned with 1 volume
methanol, 1 volume acetone, and 2 volumes milli-Q water before running samples.
Samples were stored at -20 °C until samples were eluted. Sertraline standards (2-8 mg/l)
were made in methanol/1%. Cartridges were eluted with methanol/1% acetic acid and
stored in sample vials for HPLC analysis. Samples were run on a Waters HPLC with
1525 Breeze HPLC pump, Waters 717 Plus auto sampler, and Waters 2487 absorbance
detector set at 270 nm (Waters, Milford, MA, USA). The mobile phase consisted of
50:40:10:0.3:0.15 water: acetonitrile: methanol: triethylamine: acetic acid set at a flow
rate of 1 ml/min and an injection volume of 40 µl. An Alltech Prevail C18 column
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(150mm, 4.66 I.D.) was used for separation. Approximate run time was 12 minutes with
sertraline eluting off the column at 8 minutes.
Brain preparation
Bass were euthanized in MS-222 (1.5 g/L MS222 buffered with CaCO3 (pH 7.07.5)). Fish were pithed, brains removed and flash frozen in liquid nitrogen before being
transferred to -80°C freezer until processed. Brains were thawed, weighted and
transferred to a 1.5 ml micro centrifuge tube. Before sonication, 50 µl of 2.5 mg/L
fluoxetine D5 internal standard was added with 50 µl of Milli Q water. Brains were
sonicated for 10 seconds at 10% amplitude. Immediately following sonication, 200 µl of
freezing acetonitrile was added to each brain, vortexed and placed back in the -80°C to
allow proteins to precipitate. Brains were then centrifuged at 17,000 G for 5 minutes at
4°C. Supernatant was removed and placed in a new micro centrifuge tube and placed
back in the -80°C again to allow proteins to precipitate. Samples were centrifuged 4 times
to ensure all debris was removed. Samples were then placed in LC-MS/MS tubes for
analysis. An aliquot of each brain sample was diluted 1:10 in Milli Q water and run using
the manufacturer’s instructions. Brain antidepressant and serotonin concentrations were
normalized to brain tissue weight (g).
Plasma preparation
Bass were euthanized in buffered MS-222. BD Vacutainer tubes (Vitality
Medical, Salt Lake City, UT, USA) were used to draw blood from fish caudal artery.
Blood was immediately placed on ice, then centrifuged at 3,000 G for 10 minutes at 4°C.
Plasma was transferred to a 1.5 ml micro centrifuge tube then placed in -20°C freezer
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until processed. Plasma samples were thawed and vortexed. A 20 µl aliquot of plasma
was added to a newly labeled micro centrifuge tube with 50 µl of internal standard used
above and 150 µl of acetonitrile. Samples were vortexed before being placed back in the 20°C to allow proteins to precipitate. Samples were centrifuged twice at 17,000 G for 5
minutes at 4°C to remove all debris, re-freezing in-between centrifuges. Clear
homogenate is placed in an LC-MS/MS tube for analysis.
LC-MS/MS analysis
Table 2.1 shows the parameters used for detecting sertraline and serotonin in the
brain and plasma samples. Samples were analyzed on a Shimadzu LC-MS/MS 8030
using a kinetix column (2.6u, C18, 100 x 3.0mm). The mobile phase consisted of 0.01%
formic acid in 40% water and 60% methanol. A gradient method ran with 5% methanol
for 2 minutes, increasing from 10% methanol for 2 minutes to 95% methanol for 2
minutes, and remaining at 95% methanol for 5 minutes. The total run time was 11
minutes. At the end of the run, the mobile phase reduced back down to 5% methanol over
6 minutes to re-equilibrate the column before the next sample injection. The sample
injection volume was 5 μL and the compound retention times were as follows: Serotonin:
2.9 min, fluoxetine-d5: 9.0 min, and sertraline: 9.2 min.
PCR analysis
Bass were euthanized in buffered MS-222. Intestines were removed and divided
into proximal, medial, and distal sections. The sections were flash frozen in liquid
nitrogen before being placed in the -80°C freezer until processed.

34

Homogenization
Intestine samples were homogenized with an IKA T10 basic hand homogenizer.
Labeled 2 ml centrifuge tubes were filled with 750 µl STAT-60. A small portion of
intestine (<75 mg) was placed into the centrifuge tube and immediately homogenized on
ice in 30-second segments until all tissue was broken up. Samples then sat for 5 minutes
at room temperature to allow for complete dissociation of nucleoprotein complexes
before being put back on ice. The homogenizer was cleaned in-between samples using
four steps (70% ethanol, RNase away, Diethyl pyrocarbonate (DEPC) water, DEPC
water).
RNA extraction
One hundred fifty microliters of molecular grade chloroform were added to each
sample after the 5 minutes at room temperature and vortexed for 15 seconds, and was
incubated at room temperature for 3 minutes. Samples were centrifuged at 14,000 rpm for
15 minutes at 4°C. Three phases appeared, and the upper aqueous layer was collected
making sure not to puncture the middle lipid layer. The upper layer was placed in a new 2
ml tube with another aliquot of 750 µl STAT-60. A second RNA extraction was repeated,
and aqueous phase was transferred to a 1.5 ml tube.
RNA precipitation and reconstitution
Glycol blue was added to each sample to co-precipitate with the RNA pellet.
Seven hundred microliters of molecular grade isopropanol were added to each sample
and placed on ice for 10 minutes. Samples were centrifuged at 14,000 rpm for 45 minutes
at 4°C. Supernatant was poured off, and pellet washed with 750 µl of 75% molecular
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grade ethanol. Samples were vortexed and centrifuged at 7,500g for 5 minutes at 4°C.
Ethanol wash was repeated. After centrifugation, pellets were air dried until clear.
RNAsecure (Ambion) was heated to 60°C with a heating block. Thirty microliters of
RNAsecure were added to each pellet, vortexed, and on the heat block for 2-3 minutes.
Samples were vortexed and placed back on the heat block for an additional 10 minutes
before cooled to room temperature.
RNA quantification
A NanoDrop Lite microliter spectrometer (Thermo Scientific) was used to
determine the concentration of RNA in each sample. The machine was initialized and
blanked with 2 µl of ultrapure water. Each sample was run on the NanoDrop (the upper
limit of this machine was 1,200 ng/µl), additional RNAsecure (Ambion) was added to
samples appropriately to make sure they were within the machine limits.
DNAse treatment
One microliter of 10X reaction buffer and 1 µl Perfecta DNase I (2U/µl) (Quanta)
was added to 0.2/0.5 ml micro-tubes on ice. The amount of RNA and ultrapure water
added were variable depending on the concentration of RNA determined from the
NanoDrop. Total volume in the micro-tubes was 11 µl (1 µl 10x stop buffer was added
after incubation), and target RNA concentration per tube was 400 ng/µl. Micro-tubes
were vortexed and incubated for 30 minutes at 37°C. Stop buffer was added, and tubes
were vortexed before incubating for 10 minutes at 65°C.
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cDNA synthesis
Four microliters of qScript reaction mix (5x) and 1 µl qScript RT (Quanta) was
added to 0.2 ml thin-walled PCR tubes sitting on ice. The amount of RNA and ultrapure
water depended on the concentration of stock RNA and the concentration used. The total
volume in each tube was 20 µl. The micro tubes were vortexed and placed in a Veriti
thermal cycler (Thermos Fisher Scientific) programed for: 1 cycle at 22°C for 5 minutes,
1 cycle 42°C for 30 minutes, 1 cycle at 85°C for 5 minutes, and then held at 4°C.
Quantitative PCR
Table 2.2 gives a detailed description of the primers used. A dilution of 1:20 was
completed when preparing the PCR plate for the SERT gene analysis. Undiluted cDNA
was used for preparing the CCK PCR plate. A dilution of 1:1000 was completed for the
18S housekeeping gene. Gene primers were made up to an 18 µm concentration. SERT
and 18S PCR plates were prepared at a ratio of 10:1:1:8 master mix cyber green (2x), for
primer, rev primer, and diluted cDNA. The CCK plate was prepared at ratio of 10:1:1:2:6
master mix cyber green (2x), for primer, rev primer, undiluted cDNA, and ultrapure
water. Bio-rad IQ5 software coupled with a Bio-rad IQ5 real-time PCR detection system
was used following the method: 1 cycle at 95°C for 3 minutes, 40 cycles of 95°C for 10
seconds and 58°C for 1 minute, 1 cycle at 95°C for 1 minute, and 1 cycle at 55°C for 1
minute.
Statistics
All statistical analysis was performed using JMP Pro 12.0. The data were
transformed to log (data) + 1 to reduce data variability for analysis. A model was run
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with day, treatment, day*treatment, and tank nested within treatment as a random
variable to analyzed all time to capture prey data. Since one HSB was placed in each
tank, nesting tank within treatment and treating it as a random variable corrected for the
repeated measures of time to capture prey. A least squares mean model run with day,
treatment and day*treatment was run to make multiple comparisons for plasma and brain
data. PCR data were normalized by transforming fold change to log (data) + 1 before
using Student t to determine differences between control and treatment groups in each
intestine section.
Results
Sertraline aqueous exposure
Sertraline exposure concentrations were measured (mean ± SE) as 4.5 ± 0.84
µg/L, 35.4 ± 2.18 µg/L, and 96.8 µg/L for low, medium, and high treatment groups,
respectively. All exposure groups were within 89-97% of the nominal concentrations.
Water quality parameters were measured (mean ± SD) as 6.96 ± 0.22, 21.2 ±1.27, and 8.8
± 0.2 for pH, water temperature (C°), and dissolved oxygen (mg/L), respectively.
Behavioral assay
Exposure of hybrid striped bass to sertraline caused an increase in time to capture
prey at some feeding points over the 12-day experiment. Each prey was analyzed
separately, so prey 1 refers to time to capture the first fathead minnow, prey 2 represents
time to capture the second fathead minnow, prey 3 refers to time to capture the third
fathead minnow, and prey 4 refers to time to capture the fourth fathead minnow.
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For the time to capture prey 1 (figure 2.1), bass took significantly longer to
capture prey at the highest concentration on day 3 compared to control fish (p= 0.0255).
The low (p= 0.0671) and medium (p= 0.051) treatment groups were trending towards an
increased time to capture prey, but the statistics were not significant. Day 6 feedings
show the medium (p= 0.0004) and high (p= <0.0001) treatment groups took significantly
longer to capture prey compared to control bass. On day 6, high treatment fish time to
capture prey was significantly different than low treatment fish (p= 0.0063). The medium
and low treatment groups (p= 0.052) also were trending towards a significant difference
in time to capture prey. During the recovery period, day 9 showed no significant
difference between treatment groups. On day 12, the medium treatment group took
significantly longer to capture prey compared to the control (p= 0.0086) and low (p=
0.0366) treatment groups and trended toward significance with the high treatment group
(p= 0.0682).
For time to capture prey 2 (figure 2.2), hybrid striped bass in all sertraline
exposed treatment groups took significantly longer to capture prey compared to controls
on day 3 (p= 0.0307, 0.034, 0.0058). All sertraline treatment groups showed significant
increase in time to capture prey compared to controls on day 6 (p= <0.0001). No
statistically significant time points were observed during the recovery period (days 7-12).
For prey 3 (figure 2.3), hybrid striped bass in all sertraline exposure groups
showed significantly longer time to capture prey compared to controls on day 3 (p=
0.0299, 0.0011, 0.0016) and day 6 (p= 0.0004, 0.001, <0.0001). No statistically
significant time points were observed during the recovery period (days 7-12).
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A steep decrease in time to capture prey was observed between the last day of
sertraline exposure (day 6) and the first feeding day of the recovery period (day 9). This
pattern was observed for each prey consumed. No significant differences were seen for
time to consume the fourth prey (figure 2.4).
Brain chemistry
Whole brain serotonin levels were analyzed on each feeding day of the
experiment and normalized to brain protein concentrations in each sample. A decrease in
serotonin was detected in the medium and high treatment groups throughout the
experiment (figure 2.5). The medium treatment group showed a significant decrease in
serotonin compared to the control on day 6 (p= 0.0003). The medium treatment group on
days 3, 9, and 12 decreased but p values were just above significance levels (p= 0.0648,
0.057, and 0.058, respectively). The high treatment showed significant decrease in
serotonin levels compared to the control on days 3-9 (p= < 0.0001, 0.0474, and 0.0195,
respectively). The high treatment on day 12 decreased but was just non-significant (p=
0.0627). Serotonin levels also showed trends with time to capture prey during days 3 and
6 (figure 2.10). Time to capture prey 2 and 3 show a moderate negative relationship with
whole brain serotonin levels.
Brain antidepressant concentrations
Sertraline concentrations in the hybrid striped bass whole brain were significantly
higher in the medium and high treatments compared to control and low treatments during
the exposure period on days 3 and 6 (p = <0.0001) (figure 2.6). High and medium
treatment groups were significantly different from each other on day 3 (p = <0.0001).

40

During the recovery period, the high treatment group was significantly greater than all
other treatment groups on day 9 and 12 (p = <0.0001, <0.0007). The medium treatment
group was significantly greater than the control and low on day 9 (p = 0.0188, 0.0375).
The medium treatment group saw a large decrease in brain sertraline levels between days
3 and 6. Sertraline levels in the high treatment increased during days 3-9 before
decreasing by day 12, but still significantly increased.
Plasma antidepressant concentrations
Sertraline was detected in plasma samples from each treatment group (figure 2.7).
Some fish from the low treatment did not report sertraline detection on days 6 and 9. No
dose dependent response was seen between the treatment groups over the duration of the
experiment. Each treatment showed decreasing sertraline concentrations in the plasma
between days 3 and 9. On day 12, sertraline concentrations increased again for each
treatment group. High and low treatment groups were significantly higher than control on
days 3 (p = 0.0071, <0.0001). High and medium treatments were significantly different
on day 3 (p = 0.0062). On day 6, the high treatment was significantly higher than control
(0.0088). On day 9, the high treatment was significantly higher than all treatment groups
(p = <0.0004). High and medium treatment groups were significantly different from
control plasma (p = 0.0045, 0.0212).
Quantitative PCR data
Intestines separated into proximal, medial, and distal from high treatment fish
dissected on day 6 were analyzed for two genes (SERT and CCK). Quantitative PCR data
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showed a significant upregulation of CCK (p = 0.0397) and SERT (p = 0.0103) in the
medial section of the intestine compared to the control group (figures 2.8 and 2.9).
Discussion
Individual compound exposure can lead to different conclusions when compared
to the same compound in a mixture experiment. This study demonstrated that sertraline
hindered hybrid striped bass ability to capture prey, caused changes in serotonin levels in
the brain, and increased SERT and CCK mRNA expression in the gut. Past studies
investigating SSRI effects on hybrid striped bass predatory behavior, when exposed to
SSRIs individually or in a mixture, caused an increase in time to capture prey [21, 30-32].
One past study exposed hybrid striped bass to a mixture of SSRIs including: citalopram,
fluoxetine, and sertraline. Sweet (2015) saw a significant increase in time to capture prey
during the recovery period on days 9 and 12 [21]. In this exposure, the significant
increases in time to capture prey occurred during the exposure period on days 3 and 6.
Time to capture prey for hybrid striped bass exposed to sertraline did not demonstrate a
dose dependent response. When using higher doses of SSRIs in treatment, many different
serotonin receptors may be impacted throughout the body helping to explain atypical
dose responses in fish [1].
During recovery, all treatment groups showed similar time to capture prey on day
9 and 12 as the control after sertraline was removed on day 6. Sertraline levels in the
brain indicated the low and medium treatment group’s concentrations decreased as the
experiment progressed; while the high treatment concentrations remained elevated even
into the recovery period. One hypothesis for the low and medium treatment groups could
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be antidepressant metabolism rate in the fish body. Research showed fish metabolize
SSRIs with a member of the CYP family [33]. SSRIs can inhibit CYP enzymes, some of
which are responsible for their breakdown [34]. While all SSRIs have the same mode of
action, not all inhibit the same CYP enzymes with the same strength [34]. CYP2D6 is
one of the largest contributors in the metabolism of SSRIs, but CYP3A enzymes
metabolize sertraline [34]. Sertraline shows no evidence of inhibiting CYP3A enzymes.
We hypothesize sertraline may then be metabolized at a faster rate than other SSRIs
because it doesn’t inhibit the enzyme that metabolizes it at low enough doses. The high
treatment may have been a high enough dose to oversaturate the enzymes preventing
quick breakdown of sertraline as seen in the low and medium treatment groups.
Sertraline plasma concentrations showed an interesting trend by decreasing
between days 3 and 9 but increasing between days 9 and 12. Fish plasma pH levels range
from neutral to basic, leaving the majority of sertraline in its ionized form. Ionized
sertraline does not reach the target receptor as quickly as un-ionized sertraline, and unionized sertraline has been showed to be more toxic to fathead minnows compared to the
ionized form [28]. Ionizable compounds also tend to move away from lipid environments
[10]. The initial decrease in sertraline plasma levels from days 3-9 are hypothesized to be
the result of the drug moving to target molecules or accumulating in lipids in the fish
body, which can be supported in the high treatment with increasing concentrations of
sertraline in the brain over days 3-9. When concentration gets low enough, the compound
will go from the lipids back into the plasma causing an increase in concentrations in the
plasma seen on day 12. Brain sertraline concentrations support this hypothesis with a

43

decrease between days 9 and 12 which may be due to sertraline remobilizing into the
plasma or being metabolized.
Whole brain serotonin levels decreased during the medium and high treatment
groups which is the opposite of the expected therapeutic effect to increase extracellular
serotonin. Previous research showed short term exposure to fluoxetine caused a decrease
in brain serotonin levels in rats and Betta splendens injected with fluoxetine showed
decreased serotonin in the forebrain [35, 36]. Sweet (2015) exposed hybrid striped bass to
a mixture of SSRIs (citalopram, fluoxetine, and sertraline). Serotonin changes were
predicted based on previous work with fluoxetine, creating a relationship between
serotonin and brain fluoxetine concentrations. Sertraline affinity for SERT is 4x more
sensitive than fluoxetine, so fluoxetine predictions were multiplied by 4 [21]. The
predictions suggested the highest decrease in percent serotonin would occur on day 6 in
the highest treatment. Our exposure saw the largest decrease in the high treatment on day
3 instead of day 6. Serotonin decreases observed during the sertraline treatment loosely
followed with the predictions. Decreases continued to be observed in during the recovery
period even when time to capture prey had returned to levels similar to the control.
Research showed SSRI treatment caused an increase in SERT and serotonin receptor
expression which may help compensate for the initial antidepressant exposure [37, 38].
Seven receptor families and 14 receptor subfamilies for serotonin receptors have been
identified in mammals. All but one of those receptors has also been identified at the
molecular level in fish, though the functions of all have yet to be determined [1]. The
diversity of the serotonin receptors gives fish flexibility when responding to
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physiological and environmental challenges [39]. We hypothesize that the high treatment
may have caused an up regulation of the SERT receptor resulting in some reuptake
transporters being unaffected by sertraline which caused a return to normal physiological
serotonin levels and feeding behavior seen during the recovery period.
This research has shown that sertraline can cause an upregulation of SERT in the
bass gut, helping to support our claim that peripheral serotonergic systems are just as
important as the central nervous system when it comes to potential satiety effects [40].
CCK was upregulated during sertraline exposure in the high treatment group. CCK
release occurs when food enters the gut [41]. Bass were dissected directly after
behavioral assay was completed. Food was not seen past the medial portion of the
intestine suggesting we may have observed a change in CCK in the distal intestine if food
had been allowed to travel through the entire gut. Past research determined CCK could
alter feeding minutes after treatment with corticotrophin releasing factor (CRF) [40].
Changes in serotonin can cause changes in CRF and subsequent changes in feeding
behavior [42]. Future research may find trends between CRF and feeding behavior in
hybrid striped bass, which may help explain the feeding behavior trends better than just
brain serotonin levels. Future research would benefit from differentiating between intra
and extra cellular serotonin to prevent masking of effects when whole brain serotonin is
analyzed.
Behavioral tests have come under greater scrutiny recently due to lack of
consistency and comparability between data. This study follows two important factors
which help to make the behavioral endpoints robust. The first factor describes the amount
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of time organisms are allowed to acclimate to their experimental environment [43]. Bass
are given 9 days to acclimate to exposure tanks during individual training. The second
factor involves the time given for observing behavioral endpoints [43]. The 25 minutes
given for watching bass consume minnows allows plenty of time to for the bass to chase
down prey if it wants to do so. The robustness of our behavioral endpoints can also be
seen in the similar trends seen from exposing SSRIs to hybrid striped bass from four
different graduate students completing similar tests with different pharmaceuticals.
Conclusions
Exposing aquatic organisms to individual compounds may produce similar or
completely different results than what was shown when the individual compound is used
in a mixture. This experiment demonstrated sertraline could hinder hybrid striped bass
from quickly capturing prey. Serotonin levels in the brain fluctuated during the exposure
and recovery period, suggesting more than just serotonin may be responsible for the
predatory behavior seen. The evidence up upregulation of two key genes in the gut
suggests the peripheral nervous system carries just as much importance in mode of action
of SSRIs as the central nervous system does. Serotonin alone may not be the best
endpoint to explain the changes in behavior seen after sertraline exposure.
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Tables and Figures
Compound
Serotonin
Fluoxetined5
Sertraline

Precursor
Ion(s)

Product
Ion(s)

Dwell Time
(mSec)

Q1
(V)

CE
(V)

Q3(V)

Retention Time
(minutes)

177.2

160.1

300

-11

-13

-18

2.3

315

153.1

25

-14

-10

-17

9.22

307.1
307.1
307.1

276.05
158.95
159.95

3
3
3

-13
-13
-13

-12
-25
-30

-21
-17
-17

9.27

Table 2.1: LC-MS/MS optimization parameters for detecting serotonin, sertraline, and internal standard in plasma and
brain samples.
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Gene

Forward Primer

Reverse Primer

18S

5’-TGAAAACATTCTTGGCAAATGC-3’

5’-GCCGCTAGAGGTGAAATTCTTG-3’

SERT

5’-ACTGCTACCTTTCCCTACCT-3’

5’-CTGCCAATCAGGTTTGAGATAGA-3’

CCK

5’-TCTCCTCCAGGAAAGGTTCT-3’

5’-CATGTAGTCCCTGTCTGCTATC-3’

Table 2.2: Primers designed for q-PCR analysis of hybrid striped bass intestine.

48

Recovery

Exposure
C

B
C

A
A* *
B
A A A A

A

A
A B

A AA A

A
A A
A

Figure 2.1: Time to capture first fathead minnow (seconds) by hybrid striped bass exposed to sertraline. High treatment
was significantly different from control (day 3). * represents low and medium treatment groups p values which suggested
significance from control fish (p = 0.051-0.067). High treatment was different from low and control treatments (Day 6).
Medium treatment was different from control (Day 6). Bars represent standard error.
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Figure 2.2: Time to capture second fathead minnow (seconds) by hybrid striped bass exposed to sertraline. All treatment
groups on days 3 and 6 were significantly different than the control group. Bars represent standard error.
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Figure 2.3: Time to capture third fathead minnow (seconds) by hybrid striped bass exposed to sertraline. All treatment
groups on days 3 and 6 were significantly different than the control group. Bars represent standard error.
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Figure 2.4: Time to capture fourth fathead minnow (seconds) by hybrid striped bass exposed to sertraline. No
significant differences were seen through the duration of the experiment.
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Figure 2.5 Average serotonin concentrations normalized to weight of bass brain. Letters represent significant differences
during each day. Bars represent standard error. The medium treatment group was significantly different than the control on day
6. The high treatment group was significantly different than the control on days 3-9. There were several pairing that suggests
significance including the medium group from control on day 3, 9, and 12 (p= 0.0648, 0.0662, 0.0580, and between control
and high treatment on day 12 (p= 0.0627).
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Figure 2.6: Average antidepressant concentration in hybrid striped whole brain during sertraline exposure. Bars
represent standard error. * represents treatment groups significantly different from the control bass. Letters represent the
statistical differences between treatment groups on any given day. Bars represent standard error.

54

2500

Exposure

Recovery

Average sertraline concentration (ng/l)

B
2000

B

B
C

B

1500

A

B

A
Low

A
C

1000

A
B

Medium

A
B

A
B

high

B

500

A
A

A

A

A

A

0
3

6

9

12

Day

Figure 2.7: Sertraline plasma concentrations from hybrid striped bass exposed to sertraline over 6 days with 6 days of
recovery. Plasma concentrations in each treatment group decrease between days 3 and 9. On day 12 sertraline concentrations
increase again. The high treatment group was significantly higher than the control group on all days. The medium treatment
group was significantly higher than the control on day 12. On day 9, the high treatment group was significantly higher than all
other treatment groups. Bars represent standard error.
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Figure 2.8: Fold change for serotonin reuptake transporter (SERT) in sectioned intestine parts of hybrid striped bass
of the high treatment on day 6 of sertraline exposure. In the medial intestine, SERT was significantly upregulated on day 6
of exposure. Bars represent standard error.
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Figure 2.9: Average fold change for cholecystokinin (CCK) in sectioned intestine from hybrid striped bass of high
treatment on day 6 of a sertraline exposure. In the medial section of the intestine, CCK was significantly upregulated
compared to control fish. Bars represent standard error.
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Figure 2.10: Relationships between time to capture prey on days 3 and 6 with whole brain serotonin normalized to
brain wet weight. Fish 2 and 3 showed moderate strength negative relationships supporting when serotonin decreases, an
increase in time to capture prey is observed.
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CHAPTER THREE
EFFECTS OF CITALOPRAM ON HYBRID STRIPED BASS PEDATORY
BEHAVIOR AND BRAIN CHEMISTRY

Introduction
Antidepressants are pharmaceuticals responsible for treating many forms of
psychiatric disorders [1]. The number of antidepressant prescriptions in the United States
jumped from 254 million in 2010 to 314 million in 2015 [2]. These drugs are often
chronically administered to ensure their therapeutic effect. Antidepressants can enter the
sewage systems through unused prescription drugs being disposed of improperly and
through excretion after human usage [1, 3, 4]. Wastewater treatment plants are not well
equipped to totally remove antidepressants from incoming wastewaters [5]. Selective
serotonin reuptake inhibitors (SSRIs), a class of antidepressants, removal from
wastewaters occurs with different efficiencies, and citalopram has the highest removal
efficiency at 98% [6]. This results in consistent discharges into the environment from
wastewater treatment plants, making pharmaceuticals pseudo-persistent pollutants [7-9].
The persistence of antidepressants could create life-cycle problems for aquatic organisms
[10]. SSRIs have been detected in aquatic ecosystems at concentrations ranging from low
ng/l to µg/l [4, 7, 11-14]. Antidepressants have been shown to be transported great
distances from point source sites [4, 5].
While SSRIs are not present at overly toxic levels in aquatic environments, it’s
possible that these compounds may cause sublethal effects [15]. For example, behavioral
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endpoints could provide a sensitive ecotoxicological approach to studying SSRIs in the
environment, since behavioral mechanisms allow scientists to connect what occurs at the
biochemical level to the individual and population level [10, 15, 16]. SSRI’s primary
mode of action is to increase extracellular serotonin in the brain, and research supports
serotonin regulates changes in feeding, appetite, and locomotion [7, 8, 17, 18]. The
primary target of SSRIs, the serotonin reuptake transporter (SERT) has high conservation
between aquatic species and humans [2, 15, 19]. Hybrid striped bass (Morone chrysops x
Morone saxatilis) SERT showed 72% homology with human SERT suggesting SSRIs
cause similar effects in non-target aquatic organisms [19-21]. Therefore, it’s possible that
SSRIs present in aquatic environments may interact with SERT in fish, causing similar
biochemical and behavioral changes to humans.
Citalopram is an antidepressant in the SSRI class. Evidence suggests citalopram is
the least toxic of the SSRI drugs [6, 11]. The risk of citalopram to aquatic organisms such
as fish has not been well studied [6]. A dietary exposure study resulted in juvenile
rainbow trout showing no changes in aggression or swimming activity, while another
similar experiment saw a decrease in aggression and cortisol levels after seven days
citalopram exposure [22, 23]. Endler guppies showed a decrease in feeding at an aqueous
exposure of 15 µg/l [9]. Three-spined stickleback exposed to 0.15 or 1.5 µg/l citalopram
saw a decrease in number of attacks on prey by 37.5% after the first week of a 21 day
exposure [12].
Previous research in our lab investigated an environmentally relevant SSRI
mixture involving citalopram and observed a decrease in time to capture prey and a
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decrease in whole serotonin levels in the brain [19]. However, it is difficult to understand
the contribution of citalopram to the behavioral toxicity of this mixture without studying
citalopram in isolation. We are collecting data on how citalopram effects hybrid striped
bass. The goals of this study were to (1) determine if citalopram exposure causes a
change in the time to capture prey for hybrid striped bass, (2) determine citalopram
concentration in the brain and plasma, and (3) examine if serotonin concentrations in the
brain can help explain the behavioral changes. We hypothesized that citalopram will
cause a delay in time to capture prey with a decrease in brain serotonin levels, consistent
with previous research.
Materials and Methods
Test Chemicals
Citalopram hydrobromide was purchased from TCI chemicals. Acetone, HPLC
gde methanol, HPLC grade acetonitrile, glacial acetic acid, trace metals grade HCl,
triethylamine, Optima® LC-MS methanol, and Optima® LC-MS formic acid were
purchased from Fisher Scientific. Internal Standard fluoxetine-D5 hydrochloride was
purchased from CDN Isotopes (Quebec, Canada). MS-222 was purchased from Pentair
aquatic habitats (Apopka, FL, USA). Serotonin creatine sulfate complex and Fluka LCMS Chromasolv® water were purchased from Sigma Aldrich (St. Louis, USA). Water
used for analytical procedures, excluding LC-MS/MS, was ultra-purified using a Milli-Q
Super-Q filtration system (Millipore) with a measured resistivity of 18 MΩ x cm.
Fish
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All experiments were conducted under the supervision of Clemson University
Animal Care and Use Committee using the approved animal use protocols (AUP 2015077, AUP 2014-015). Hybrid striped bass (Morone saxatilis x Morone chrysops) were
purchased from Keo Fish Farms (Keo, AR, USA) as fingerlings. Detailed methods for
fish holding can be found in the previous chapter. Briefly, bass were kept in holding
troughs at Cherry farm aquatic research lab at Clemson University. Troughs were
constantly supplied with water (19-24°C) in a flow through system from Lake Hartwell
(Clemson, SC, USA). Bass were fed a commercialized slow sink diet during holding
from Zeigler Bros, Inc. (Gardners, PA, USA).
Fathead minnows were purchased from Anderson Minnow Farm (Lonoke, AR,
USA). Minnows were kept in 100L troughs with flow through system bringing in the
same water as above. Until use, minnows were fed a commercial diet (Tetramin®
Tropical Flakes) purchased from Dr’s Foster and Smith Inc. (Rhinelander WI, USA).
Bass Training
Once bass were of the appropriate size (23.4 ± 1.7 cm, 131 ± 28.8g), they needed
to be trained to capture live prey. Detailed methods for training can be found in previous
chapter. Briefly, bass were randomly chosen and moved to a trough for group training.
During group training, 5 minnows per bass were dropped into the trough every 3 days
over a 6 day period. On the 6th day of group training, bass were moved to individual
experimental tanks (1 bass per tank). Each bass was fed 4 fat-head minnows every 3 days
over a 6 day span. The time to capture each prey was recorded and used to determine
which fish were appropriate to use in the exposures.
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Experimental design
Hybrid striped bass were exposed to citalopram in a static system for 6 days.
Detailed experimental design can be found in the earlier chapter. Briefly, water quality
parameters (pH, DO, and temperature) were measured during the feeding events using an
YSI 556 multi-parameter instrument (Yellow Springs Instruments). On the last individual
training day (exposure day 0), 4 fathead minnows were dropped into the tank. Bass who
ate at least 3 fat-head minnows (with comparable feedings on the previous training days)
were used in the exposure. Water in the tanks was filled to 80L and marked before
turning the water off and spiking the tanks. Each bass was randomly assigned to a
treatment (5 bass/treatment/time point), and spiked with the appropriate volume of
sertraline to reach nominal concentrations. Feeding days took place on days 3 and 6.
After each feeding, 5 bass per treatment were euthanized for brain, plasma, and intestine
analysis.
Citalopram exposure
Stock solutions (prepared fresh daily) of citalopram were prepared by dissolving
citalopram HBr in methanol and the added to tanks to reach their nominal concentrations.
Low, medium, and high exposures were performed in addition to a control. The highest
concentration equivalent of methanol was added to each control tank to ensure no toxicity
from the carrier solvent. Methanol was at a concentration less than 0.1 mg/L; compliant
with ASTM international recommendation for experiments involving fish (ASTM1241-
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05) [24]. Two hours after tanks were spiked, appropriate aliquots from each tank were
taken to measure citalopram concentrations.
Citalopram analysis
Citalopram concentrations were analyzed on day 0, 2 hours after the spiking of
tanks. Water samples were acidified with 2-3 drops 2N HCl (pH of 3.0) and extracted
using C-18 solid phase extraction cartridges. Cartridges were conditioned with 1 volume
methanol, 1 volume acetone, and 2 volumes milli-Q water before running samples.
Samples were stored at -20 °C until analysis preparation. Cartridges were eluted with
methanol/1% acetic acid and stored in sample vials for HPLC analysis. Samples were run
on a Waters HPLC with 1525 Breeze HPLC pump, Waters 717 Plus auto sampler, and
Waters 2475 multi wavelength fluorescence detector set to excitation of 250 nm and
emission of 325 nm (Waters, Milford, MA, USA). The mobile phase consisted of
50:40:10:0.3:0.15 water: acetonitrile: methanol: triethylamine: acetic acid set at a flow
rate of 1 ml/min and an injection volume of 40 µl. An Alltech Prevail C18 column
(150mm, 4.66 I.D.) was used for separation. Approximate run time was 12 minutes with
citalopram eluting off the column at 7.2 minutes.
Brain and plasma preparation
Detailed methods for tissue preparation can be found in the earlier chapter.
Briefly, bass were euthanized in buffered MS-222. Brains were removed and kept at 80°C until processed. Brains were thawed, weighed, and sonicated with the addition of an
internal standard, Milli Q water, and acetonitrile. Brains were refrozen to allow proteins
to precipitate. Samples were centrifuged up to 4 times at 17,000 G for 5 minutes at 4°C

70

before being placed in LC-MS/MS tubes for analysis. Brain antidepressant and serotonin
concentrations were normalized to brain tissue weight (g).
Blood was removed from fish caudal artery and placed on ice until centrifugation
to collect plasma. Samples were kept at -20°C until processed. A 20 µl aliquot of plasma
was added to a centrifuge tube with internal standard and acetonitrile. Samples were
vortexed before being placed back in the -20°C to allow proteins to precipitate. Samples
were centrifuged twice at 17,000 G to remove all debris. Clear homogenate is placed in a
LC-MS/MS tube for analysis.
LC-MS/MS analysis
Table 3.1 shows the parameters used for detecting citalopram and serotonin in the
brain and plasma samples. Samples were analyzed on a Shimadzu LC-MS/MS 8030
using a kinetix column (2.6u, C18, 100 x 3.0mm). The mobile phase consisted of 0.01%
formic acid in 40% water and 60% methanol. An isocratic method ran with 5% methanol
for 2 minutes, increasing from 10% methanol for 2 minutes to 95% methanol for 2
minutes, and remaining at 95% methanol for 5 minutes. The total run time was 11
minutes. At the end of the run, the mobile phase reduced back down to 5% methanol over
6 minutes to re-equilibrate the column prior to the next sample injection. The sample
injection volume was 2 μL and the compound retention times were as follows: Serotonin:
2.9 min, citalopram: 8.8 min, fluoxetine-d5: 9.0 min.
Statistics
All statistics were performed using JMP Pro 12.0. The data was transformed to
log (data) + 1 to reduce data variability for analysis. A model was run with day,
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treatment, day*treatment, and tank nested within treatment as a random variable to
analyzed all time to capture prey data. Since one HSB was placed in each tank, nesting
tank within treatment and treating it as a random variable corrected for the repeated
measures of time to capture prey. A least squares mean model run with day, treatment
and day*treatment was run to make multiple comparisons for plasma and brain data.
Results
Aqueous citalopram concentrations
Water concentrations (mean ± SE) for citalopram were measured as 70.8 ± 5.19
µg/L, 126.3 ± 3.84 µg/L, and 190.0 ± 9.81 µg/L for low, medium, and high treatments,
respectively. All aqueous water concentrations were within 80% of the nominal
concentrations. Water quality parameters were measured (mean ± SD) as 6.98 ± 0.25,
22.5 ± 1.43, and 8.81 ± 0.21 for pH, water temperature (C°), and dissolved oxygen
(mg/L), respectively.
Behavioral assay
Exposure of hybrid striped bass to citalopram caused an increase in time to
capture prey at some feeding points over the 6 day experiment. Each prey was analyzed
separately, so prey 1 refers to time to capture the first fathead minnow, prey 2 represents
time to capture the second fathead minnow, prey 3 refers to time to capture the third
fathead minnow, and prey 4 time to capture the fourth fathead minnow.
The medium treatment group showed a significant increase in time to consume
prey 1 compared to the low (p= 0.0292) and high (p= 0.0167) treatment only on day 6
(figure 3.1). The high treatment took significantly longer to eat prey 1 compared to the
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low treatment on day 3 (p= 0.0128). The medium treatment took significantly longer to
capture the second prey from all the other treatment groups on day 3 (p= 0.0491, 0.0062,
00048) and day 6 (p= 0.0019, 0.0022, 0.0023) (figure 3.2). The medium treatment bass
took significantly longer to eat the third prey compared to all other treatment groups on
day 3 (p= 0.0034, 0.0041, 0.0009) and day 6 (p= 0.0431, 0.0117, 0.0012) (figure 3.3).
The medium and high treatments took significantly longer to eat the fourth prey
compared to the low treatment on day 3 (p = 0.0028 and 0.0452) (figure 3.4). The
medium treatment took significantly longer to capture the fourth prey compared to the
low treatment on day 6 (p = 0.0249).
Brain chemistry
No significant decreases in serotonin levels were seen during the 6 day citalopram
exposure (figure 3.5).
Brain antidepressant concentrations
Citalopram concentrations in the brain increased with treatment group in a dose
dependent fashion (figure 3.6). Medium and high treatments had significantly higher
values than the control treatment on days 3 (p= 0.0361, 0.0048) and 6 (p= 0.007, <
0.0001). Medium and high treatments had significantly higher values than the low
treatment on days 3 (p= 0.0227, 0.002) and 6 (p= 0.0194, < 0.0001). Medium and high
treatment groups differed on day 6 (p= 0.0083). There was an increase in brain
citalopram concentrations between days 3 and 6. Some low treatment bass had no
citalopram detected in their brain.
Plasma antidepressant concentrations
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Citalopram detected in the plasma on day 3 of the exposure showed increasing
antidepressant concentration in the plasma with increasing aqueous antidepressant
concentrations (figure 3.7). Plasma concentrations at the low treatment were significantly
different from those at the high treatment (p= 0.04). Day 6 plasma concentrations
decreased from those on Day 3 for the low and high treatments. The medium treatment
group plasma levels increased from day 3 to 6. The medium and high treatments were
significantly higher than the low treatment (p= 0.001 and 0.002, respectively).
Discussion
Previous research suggested citalopram caused changes in behavior but failed to
show a dose dependent response typical of some toxicants [6, 11]. The medium treatment
was the only group to show an increase in time to capture prey during the six day
exposure (figures 3.1-3.3). Kellner et al. (2015) saw citalopram effect the three-spined
stickleback in a non-dose dependent fashion. The three spined stickleback was exposed
for 21 days to citalopram where a decrease in attacks on prey occurred in the 0.15 and 1.5
µg/l concentrations [12]. The Endler guppy was chronically administered citalopram for
21 days during which time the 15 µg/l group showed decreased feeding behavior [9].
Two different experiments were completed with trout, where one (using fry) showed no
changes in behavior while the other (using two year old fish) demonstrated a decrease in
aggression [22, 23]. Differences in citalopram exposure may be a result of age, species,
and food web status. Fish intermediate in the food web (guppies and stickleback) have
different behaviors compared to larger predatory fish (trout and bass). Previous research
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does show citalopram can have an effect on fish behavior, but few studies have been
completed with larger predatory fish which would be a more beneficial comparison.
Citalopram plasma concentrations leveled off over the 6-day exposure. Previous
research with a SSRI mixture did not see plasma levels change between 48 and 72 hours
[19]. A maximum concentration in the plasma may have been reached at 72 hours during
our citalopram exposure, with any additional citalopram moving to lipid tissues or being
metabolized.
The brain showed a dose dependent increase in citalopram on both days 3 and 6
of the exposure. Changes in behavior were only seen in the medium treatment when
larger concentrations of citalopram were detected in the brain during the high treatment.
One hypothesis could be an unfavorable ratio of citalopram enantiomers in the high
treatment. Citalopram is a racemic mixture where the S- (citalopram) form can interact
with the S+ (escitalopram) form, blocking interaction with SERT [25]. Even though a
higher concentration of citalopram was detected in the high treatment brains compared to
the medium, the medium may have had a more favorable ratio for causing an effect on
feeding behavior. A second hypothesis to explain high citalopram concentrations in the
brain is the drug has poor blood brain penetration [26]. Serotonergic neurons in the brain
are located in large concentrations in the telencephalon and brainstem raphe nuclei. The
serotonergic neurons branch off into the hippocampus, hypothalamus, and isthmus [2, 7].
Citalopram may not be reaching the interior portions in the brain at high enough
concentrations to cause behavioral changes. When brains were dissected blood was also
collected with the brains, and high citalopram concentrations may have resulted from the
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drug in the blood surrounding the brain or just past the blood brain barrier. A third
hypothesis to explain citalopram in the brain but no change in behavior is binding
affinity. Citalopram was ranked third behind fluoxetine and sertraline in binding affinity
to hybrid striped bass SERT [19]. At the low treatment, citalopram may not have been
prevalent enough to bind tightly to SERT causing a downscale change in feeding
behavior.
No significant changes in brain serotonin were seen over the 6 day citalopram
exposure. Sweet (2015) predicted no large percent change in citalopram only exposure to
hybrid striped bass based on the binding affinity of the compound [19]. Rainbow trout
exposed to citalopram for seven days did not show any changes in aggression compared
to controls. Researchers suggested that the seven day exposure may not have been
enough time for an effect to be observed [23]. Due to the low toxic nature of citalopram
and low binding affinity to the hybrid striped bass SERT, a longer exposure period may
have been needed to see an effect on serotonin levels [19]. One review suggested that
SSRI exposure should take place for 21 days or longer because the therapeutic effects
occur weeks after administration of the drug has begun [2]. Serotonin effects many
hormones within the brain, including corticotrophin releasing factor, which are suggested
to cause a decrease in feeding behavior [18, 27]. Measuring additional endpoints may
have led to a better explanation of why the medium treatment group showed a decrease in
time to capture prey without a change in serotonin.
Our whole brain analysis of serotonin may have masked any serotonin changes
since we did not differentiate between different parts of the brain or intra and extra
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serotonin levels [2]. Evidence has shown that serotonin levels changed in different parts
of the brain when exposed to fluoxetine [28, 29]. Fluoxetine in one experiment showed
no differences in biochemical activity in the telencephalon and hypothalamus [29].
Differences in serotonin were detected after chronic fluoxetine exposure to Siamese
fighting fish in the forebrain and hindbrain [28]. Fluoxetine levels in these studies were
measured in whole brain vs separate sections. Because we did whole brain analysis of
serotonin and citalopram, we could be overlooking evidence where citalopram is not
traveling to the right parts of the brain to cause a behavioral effect in the low and high
treatments.
Sublethal changes in behavior such as feeding could alter the ecological fitness of
an individual or population if exposure continues for several generations which could
happen with continued release of SSRIs into the environment [7-9, 17]. Citalopram
research on aquatic organisms has not been sufficiently completed to the same extent as
fluoxetine [6]. Behavioral tests are useful for seeing sublethal effects because the most
sensitive endpoints include locomotion behaviors [17]. Our study met two standards for
having robust behavioral endpoints. Our fish were allowed to acclimate for six days prior
to exposure and behavioral tests were completed for 25 minutes per feeding time [30].
Industrial contaminants are used for making ecological regulations, but antidepressants
work differently than industrial compounds and are not good substitutes [31]. Research
needs to continue looking into less studied compounds such as citalopram. Many
organisms are exposed to multiple compounds in the environment, understanding
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individual compounds could give insight as to what combined effect (antagonistic,
additive, and synergistic) occurs within the mixtures.
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Figures and Tables
Compound

Precursor
Ion(s)

Product
Ion(s)

Dwell Time
(mSec)

Q1
(V)

CE
(V)

Q3(V)

Retention Time
(minutes)

Serotonin

177.2

160.1

300

-11

-13

-18

2.3

325.2

109.05

3

-14

-26

-23

325.2

262.05

3

-14

-21

-19

325.2

116.05

3

-14

-28

-25

315

153.1

25

-14

-10

-17

Citalopram
Fluoxetined5

8.94

9.22

Table 3.1: LC-MS/MS optimization parameters for detecting serotonin, citalopram, and internal standard in plasma
and brain samples.

79

Time to Consume First Prey
700

Time to consume prey (seconds)

600
500

*
400
control
Low

300

Medium
High

200
100
0
0

3

6

Day

Figure 3.1: Time to capture the first fathead minnow (seconds) for hybrid striped bass when exposed to citalopram. The
medium treatment group took significantly longer to capture prey compared to the medium and high treatment groups on day
6.

80

Time to consume second prey
1200

Time to Consume Prey (Seconds)

1000

*
800
Control

600

*

Low
Medium

400

High

200

0
0

3

6

Day

Figure 3.2: Time for hybrid striped bass to consume the second prey (seconds) when exposed to citalopram. The
medium treatment group took significantly longer to capture prey compared to all other treatment groups on days 3 and 6.
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Figure 3.3: Time for hybrid striped bass to consume the third prey (seconds) after exposure to citalopram. The medium
treatment group took significantly longer to capture prey compared to all other treatment groups.
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Figure 3.4: Time for hybrid striped bass to consume the fourth prey (seconds) after exposure to citalopram. The
medium and high treatment took significantly longer to capture prey compared to the low treatment on the 3rd day. The low
and medium treatments were significantly different on the 6th day.
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Figure 3.5: Whole brain serotonin levels in hybrid striped bass after sertraline exposure normalized to wet weight of
brains (g). No significant differences were seen in serotonin levels.
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Figure 3.6: Citalopram levels in the whole brain of hybrid striped bass exposed to citalopram. On day 3, medium and
high treatments were significantly higher than the low treatment. On day 6, each treatment group was significantly different
from each other. The medium and high treatments were also significantly higher than the control groups on both days 3 and 6.
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Figure 3.7: Citalopram concentrations found in hybrid striped bass plasma samples during citalopram exposure. On
day 3, the low and high treatment groups showed significantly different plasma citalopram concentrations. On day 6, medium
and high treatment groups were significantly higher than the low treatment group.
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CHAPTER FOUR
FINAL DISCUSSION AND CONCLUSIONS

Comparison of SSRI mixtures and individual SSRI exposures
This thesis is an extension of previous work in which Sweet (2015) investigated
changes in hybrid striped bass predatory behavior after exposure to a mixture of selective
serotonin reuptake inhibitors (SSRIs) including citalopram, fluoxetine, and sertraline [1].
Gaworecki et al. (2008) completed a study that exposed hybrid striped bass to fluoxetine
only [2]. This thesis studied citalopram and sertraline only exposures to hybrid striped
bass to complete the mixture comparison. Figures 4.1-4.4 compare the high exposure
treatment from the mixture study to the low exposure treatments from the individual
SSRI studies. Table 4.1 shows the concentrations for each treatment chosen in the
comparison to confirm the similarities in the aqueous exposure concentrations. All
studies followed a similar experimental setup with six days of exposure and six days of
recovery.
Understanding how individual compounds interact in a mixture can help with
determining environmental toxicity to non-target organisms, since mixture interactions
can cause a different response than individual exposure reactions. When the components
of a mixture work according to the same mode of action and do not interfere with one
another they are said to act additively. When the components in a mixture create a greater
than expected effect, the result is synergism. When the component’s combined effect is
smaller than expected the interaction is antagonistic [3]. SSRI’s comparable structures
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and mode of actions would support an additive interaction among members of this drug
class [4].
On day 3, fluoxetine and sertraline exposed fish took longer to capture prey
compared to the mixture and citalopram studies. The mixture time to capture prey was
well below fluoxetine and sertraline for the first two prey, but started to reach sertraline
levels for the third prey (figure 4.1). The individual SSRIs may have inhibited each other
in the mixture study resulting in the decreased time to capture prey observed. On day 6
and 9, fluoxetine fish took longer to capture prey than all the other studies, and sertraline
and citalopram were below the mixture study (figure 4.2 and figure 4.3). Sertraline and
citalopram may have had some antagonistic effects on fluoxetine during the end of the
exposure and beginning of the recovery period resulting in lowered time to capture prey
for the mixture study. On day 12, the mixture treatment took longer to capture prey
compared to sertraline and fluoxetine studies (figure 4.4) (no citalopram data was
available for the recovery period). Fluoxetine and sertraline may have acted
synergistically, with fluoxetine playing the largest role, between days 9 and 12 causing
the increase in time to capture prey observed.
Despite the comparable mode of action of the investigated SSRIs, comparing the results
of the mixture studies with the exposures to individual components of the mixture
suggests these drugs do not act synergistically. This may be caused by differences in
binding affinity for the serotonin reuptake transporter (SERT), competition for SERT in
the mixture exposure, and other pharmacokinetic interactions that could cause deviations
from a simple additive relationship.
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Pharmacokinetic properties of SSRIs have been poorly studied in aquatic species.
One study looked at some properties of fluoxetine on Japanese medaka and reported that
fluoxetine has a high Volume of Distribution, with a calculated bioconcentration factor of
80, and that fluoxetine is more acutely toxic than fluvoxamine, paroxetine, and
citalopram [5]. Brook trout exposed to 20% v/v wastewater effluent saw similar tissue
level accumulations of citalopram, fluoxetine, and sertraline in the liver and brain [6].
Pharmacokinetics of SSRIs in humans has been well studied. Research determined that
fluoxetine is completely absorbed after oral administration and has the largest volume of
distribution (Vd) (14-100 L/kg) among the SSRI drugs, in part due to lysosomal trapping
in tissues [7]. Fluoxetine is extensively metabolized into norfluoxetine which retains
SSRI properties, and both fluoxetine and norfluoxetine have relatively long half-lives of
up to four days [7]. Sertraline is completely adsorbed from the intestine by eight hours
after ingestion and has a Vd exceeding 20 L/kg. Sertraline is quickly metabolized into Ndesmethylsertraline which has a half-life 3x longer than the parent compound [7].
Citalopram is considered one of the safest SSRIs when examining pharmacokinetic drug
interactions. Citalopram is metabolized into two primary metabolites which occur in
racemic mixtures with the S+ enantiomer retaining SSRI properties, but the Senantiomer is found at higher concentrations [7]. All these differences in absorption,
distribution, metabolism and excretion of the individual SSRIs influence the eventual
concentration at the receptor site, and thus influence the toxicological endpoints.
Thus, determining how pharmaceuticals interact in a mixture proofs to be
challenging. This research supported a non-additive relationship between the SSRIs
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fluoxetine, sertraline, and citalopram. Sertraline would likely contribute to the mixture
study more than citalopram due to the lower binding affinity citalopram has for the
hybrid striped bass serotonin reuptake transporter [1]. In the environment, SSRIs would
be in a mixture with a variety of other pharmaceuticals. In these complex mixtures seeing
effects that fall into the synergistic or antagonistic category are rare [8]. While this SSRI
only comparison supports evidence of both synergistic and antagonistic effects in
mixtures, in more complex environmental mixtures, only a few compounds may be the
driving force in mixture interactions, while those same compounds also buffer the effects
of other smaller synergistic and antagonistic interactions [8, 9]. A more in-depth
experiment using wastewater effluent with known concentrations of SSRIs would give
further information on how SSRIs work in a more complex mixture setting.
Conclusions
1. When comparing the individual SSRI experiments to the mixture study,
fluoxetine appears to play the largest role in the effect on time to capture
prey by hybrid striped bass.
2. Sertraline and citalopram may have inhibited some of the toxic effects of
fluoxetine during the exposure period in the mixture.
3. Brain serotonin levels alone may not be enough to explain the behavioral
effects observed from SSRI exposure in hybrid striped bass.
4. The peripheral nervous system should be further investigated for changes
after an exposure to SSRIs occurs, rather than just focusing on changes in
brain chemistry.
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Figures and Tables
Treatment
Mixture- high trt
Sweet (2015)

Actual aqueous concentrations
(µg/l)
4-sertaline
16-fluoxetine
84-citalopram

Sertraline only- low trt

4.5

Fluoxetine only- low trt
Gaworecki et al. (2008)

23.2

Citalopram only- low trt

70.8

Table 4.1: Aqueous water concentrations from treatments used in the comparison
of a SSRI mixture and individual SSRI exposures.
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Figure 4.1: Comparing time to capture prey 1, 2, and 3 on day 3 after exposure to SSRIs individually or in a
mixture. Fluoxetine only exposure time to capture prey is higher than all the other SSRI studies. Sertraline is higher than the
mixture study, but the mixture study time to capture prey reaches sertraline levels by the third prey. Citalopram time to capture
prey is well below the other SSRI studies.
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Figure 4.2: Comparing time to capture prey 1, 2, and 3 on day 6 after exposure to SSRIs individually or in a mixture.
The fluoxetine study took longer to capture prey than the other SSRI studies. The sertraline study was close in time to capture
the 2nd prey to the mixture study. Citalopram time to capture prey was well below the other SSRI studies.
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Figure 4.3: Comparing time to capture prey 1, 2, and 3 on day 9 after exposure to SSRIs individually or in a mixture.
Fluoxetine took longer to capture prey compared to the mixture and sertraline studies. Citalopram was not studied to day 9, so
no data was available for comparison. Sertraline was well below the mixture and fluoxetine studies.
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Figure 4.4: Comparing time to capture prey 1, 2, and 3 on day 12 after exposure to SSRIs individually or in a mixture.
The mixture study took longer to capture prey compared to fluoxetine and sertraline studies. Fluoxetine took longer to capture
prey compared to the sertraline study. Citalopram was not studied on day 12, so no data was available for comparison.
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